The expression of Nrx-1Scer\UAS.cLa under the control of Scer\GAL4elav.PU leads to a significant increase in the number of synaptic boutons at the third instar larval neuromuscular junction, as compared to controls.
Expression of Nrx-1Scer\UAS.cLa pan-neuronally using Scer\GAL4elav-C155 or Scer\GAL4C380 significantly enhances the formation of synaptic boutons compared to wild-type. Increasing Nrx-1 gene dosage in all neurons by one copy results in over a 30% increase in the number of synaptic boutons, while increasing it by two copies results in more than 40% enhancement.
Expression of either one or two copies of Nrx-1Scer\UAS.cLa in muscle cells, under the control of Scer\GAL4C57 does not result in any significant change in bouton number.
Nrx-1UAS.cLa, Scer\GAL4elav.PU has neuromuscular junction | third instar larval stage phenotype, suppressible by witB11/witA12
Nrx-1UAS.cLa, Scer\GAL4elav.PU has terminal bouton | third instar larval stage phenotype, suppressible by witB11/witA12
Scer\GAL4elav.PU/Nrx-1UAS.cLa is a non-suppressor of neuromuscular junction | third instar larval stage phenotype of witB11/witA12
Scer\GAL4elav.PU/Nrx-1UAS.cLa is a non-suppressor of terminal bouton | third instar larval stage phenotype of witB11/witA12
The third instar larval neuromuscular junctions of individuals that both express Nrx-1Scer\UAS.cLa under the control of Scer\GAL4elav.PU and are witB11/witA12 transheterozygous show a decrease in the number of synaptic boutons similar to what is observed in witB11/witA12 transheterozygotes, rather than the increase induced by the expression of Nrx-1Scer\UAS.cLa.
The expression of Nrx-1Scer\UAS.cLa under the control of Scer\GAL4elav.PU rescues the decreased number of synaptic boutons observed at the Nrx-1273 homozygous third instar larval neuromuscular junction.